Steris Healthcare: Committed to Quality Healthcare and Pharmaceutical Excellence

 STERIPHYLLIN ERDO Tablet: Complete Guide to Acebrophylline-Erdosteine for Respiratory Relief

Acebrophylline and Erdosteine Tablets bring together two complementary respiratory agents into a single formulation designed for long-term airway management. Acebrophylline is a bronchodilator with anti-inflammatory properties that relaxes the airway muscles, making breathing easier, while Erdosteine is a mucolytic that breaks down thick mucus, making it easier to cough out and clear the airways. Together, these ingredients help relieve symptoms such as persistent cough, chest congestion, wheezing, and shortness of breath. STERIPHYLLIN ERDO reflects a growing clinical trend in respiratory medicine — combining airway-relaxing and mucus-clearing agents into one tablet to address the two core problems patients with chronic bronchitis and COPD face: narrowed airways and excessive, hard-to-clear mucus. 

Why It's Important

Chronic respiratory conditions like COPD and chronic bronchitis are progressive, long-term diseases that significantly affect a patient's daily quality of life, often driven by two interconnected problems — airway constriction and excessive mucus production that clogs the airways further. Treating only one of these issues typically leaves patients with incomplete relief: bronchodilation alone doesn't address the mucus burden causing chest congestion, while a mucolytic alone doesn't ease the muscular tightness that makes breathing feel labored. This growing recognition has led pharmaceutical innovation toward combination formulations, with the launch of India's first Acebrophylline-Erdosteine bi-layered tablet designed specifically to enhance lung function and manage chronic bronchitis in COPD patients. STERIPHYLLIN ERDO's dual-action formulation is important precisely because it addresses this treatment gap, offering patients more complete symptomatic relief through a single, convenient tablet rather than requiring separate prescriptions for bronchodilation and mucolytic therapy. 

Key Benefits of STERIPHYLLIN ERDO

What Are the Benefits of This Combination?

• Eases breathing difficulty — Acebrophylline functions as a bronchodilator and mucoregulator, effectively stimulating surfactant production and reducing bronchial hyper-responsiveness 
• Clears thick, sticky mucus — Erdosteine acts as a potent mucolytic agent, breaking down mucus to make it easier to expel 
• Reduces airway inflammation — Acebrophylline's anti-inflammatory properties help soothe irritated airways alongside its bronchodilating effect 
• Relieves persistent cough and chest congestion — helps relieve symptoms such as persistent cough, chest congestion, wheezing, and shortness of breath 
• Supports long-term respiratory management — commonly prescribed by healthcare professionals for patients with chronic respiratory diseases requiring sustained symptom control 
• Dual mechanism convenience — addresses both airway constriction and mucus burden in a single, easy-to-follow tablet regimen

Side Effects

STERIPHYLLIN ERDO is generally well tolerated, but as with all respiratory medications, some patients may experience side effects, including:

• Mild nausea or stomach upset
• Headache
• Dizziness
• Dry mouth
• Mild heartburn or acid reflux

Serious Side Effects 

Patients should seek immediate medical attention if they experience:

• Signs of an allergic reaction, such as skin rash, swelling of the face or throat, or difficulty breathing
• Rapid or irregular heartbeat
• Severe or persistent abdominal pain
• Signs of liver dysfunction, such as yellowing of the skin or eyes
• Worsening breathing difficulty despite treatment, which may indicate the need for medical reassessment

Available Substitutes 

Theon Pharmaceuticals holds the distinction of being the first company in India to receive a DCGI license for a bi-layered Acebrophylline-Erdosteine tablet formulation, making it a directly comparable branded alternative in this emerging combination category. Patients may also encounter single-ingredient alternatives, such as Acebrophylline-only formulations like BRELIFT-100, which work by relaxing airway muscles, reducing inflammation, and thinning mucus. Since this is a relatively newer combination category in the Indian market, patients should consult their pulmonologist before switching between available brands, as exact ratios and release mechanisms (single-layer versus bi-layered) may differ. 

Dosage Guidelines 

STERIPHYLLIN ERDO should be taken exactly as directed by your doctor and is not intended for the immediate relief of sudden asthma attacks. The typical dosage is generally one tablet, taken once or twice daily depending on the severity of the condition and physician assessment, preferably with food to minimize the likelihood of gastric discomfort. Duration of therapy is usually determined based on the chronic nature of the underlying respiratory condition and should be reviewed periodically with the treating pulmonologist or physician. 

Precautions & Warnings

• This medication is not intended for the immediate relief of sudden asthma attacks — a fast-acting rescue inhaler should be used for acute breathing emergencies as advised by your doctor 
• Use with caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding
• Should be used cautiously in patients with liver or kidney impairment, with dose adjustment as advised by the physician
• Not recommended for patients with a known hypersensitivity to Acebrophylline, Erdosteine, or related compounds
• Avoid alcohol consumption during treatment, as it may increase the risk of gastrointestinal side effects
• Not advised during pregnancy or breastfeeding unless specifically directed by a physician
• Inform your doctor of all other medications being taken, particularly other bronchodilators or respiratory medications, to avoid potential interactions
• Patients should continue any other prescribed respiratory medications unless advised otherwise by their doctor

Mechanism of Action

STERIPHYLLIN ERDO works through two complementary pharmacological pathways targeting different aspects of chronic respiratory disease. Acebrophylline functions as a bronchodilator and mucoregulator that stimulates surfactant production and reduces bronchial hyper-responsiveness, while its anti-inflammatory properties help soothe irritated airways, effectively relaxing constricted bronchial smooth muscle and reducing the airway's tendency to react excessively to irritants. This dual bronchodilator-mucoregulator action helps widen the airways while also promoting healthier mucus consistency. Erdosteine, meanwhile, acts as a potent mucolytic agent, working by breaking the disulfide bonds within thick mucus glycoproteins, which reduces mucus viscosity and makes it substantially easier for patients to cough out and clear from the airways. Erdosteine is also recognized for its antioxidant properties, which may help protect airway tissue from oxidative damage associated with chronic inflammation. Together, these two mechanisms address both the muscular and secretory components of chronic obstructive airway disease, offering more comprehensive symptomatic relief than either agent could provide alone. 

Conclusion

STERIPHYLLIN ERDO by Steris Healthcare offers a modern, dual-action approach to managing chronic respiratory conditions like COPD and chronic bronchitis, combining Acebrophylline's bronchodilator and anti-inflammatory action with Erdosteine's powerful mucolytic effect. For patients dealing with persistent cough, chest congestion, and breathing difficulty associated with long-term airway disease, this combination offers a convenient, well-targeted therapeutic option that addresses both airway constriction and mucus burden — supporting better day-to-day respiratory comfort when used consistently under medical supervision.